月経前症候群治療の市場：薬剤タイプ、種類、流通チャネル別- 2025-2030年の世界予測

月経前症候群の治療市場は、2023年に17億2,000万米ドルと評価され、2024年には17億9,000万米ドルに達すると予測され、CAGR 4.35％で成長し、2030年には23億2,000万米ドルに達すると予測されています。

月経前症候群（PMS）治療市場は、月経を迎える人のかなりの割合が罹患するPMSの症状を緩和するために設計された一連の治療法と製品を中心に展開しています。この市場の必要性は、身体的、感情的、行動的な症状を引き起こし、日常生活や生活の質に大きな影響を与えるPMSが広く蔓延していることからも明らかです。PMS治療薬の用途は、市販薬、サプリメント、生活習慣の改善から、気分の落ち込み、腹部膨満感、けいれんなどの特定の症状に対処するための処方療法まで多岐にわたる。エンドユーザーは主に、これらの症状の緩和を求める個人であり、自己治療を行っている人と医師の監督下にある人の両方を含みます。この市場の成長は、意識の高まり、女性ヘルスケアにおける進歩、個別化医療への嗜好の高まりに大きく影響されています。ホルモンベースの治療法、植物由来の治療法、症状の追跡と管理のためのデジタルヘルスソリューションの開発には機会が存在します。しかし、この市場は、現在の治療法の副作用や、オープンな議論や診断を妨げる社会的偏見といった制約に直面しており、さらに新しい治療法の承認における規制上の課題もあります。さらに、PMSは多面的な性質を持つため、万能な治療法が存在しないことも課題となっています。非ホルモン治療の選択肢、個別化治療のための人工知能、患者関与を強化するためのモバイルヘルス技術などの革新が模索される可能性があります。PMSの原因となる特定の遺伝的要因、ホルモン要因、生活習慣要因に関する調査は、より的を絞った介入のための洞察を提供する可能性があります。PMS治療市場はダイナミックであり、包括的な症状緩和を提供する効果的なソリューションに対する需要が絶え間なく続いています。治療企業は、患者中心のアプローチに注力し、偏見をなくすための啓発キャンペーンを展開し、医療専門家と協力して治療プロトコルを最適化することで、満たされていないニーズを活用し、市場の成長と患者の転帰の改善につなげる可能性があります。

市場力学：急速に進化する月経前症候群の治療市場の主要市場インサイトを公開

月経前症候群の治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 月経前症候群に関する診断意識の高まり
  • オンラインチャネルを通じたPMS治療製品の容易な入手可能性
• 市場抑制要因
  • PMS治療薬および機器の製品回収に関連する問題
• 市場機会
  • PMS治療の進歩と新薬の出現
  • ウェアラブル技術の採用とデジタルヘルスの普及
• 市場の課題
  • PMS管理に関する社会的障壁とスティグマ化

ポーターのファイブフォース：月経前症候群の治療市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：月経前症候群の治療市場における外部からの影響の把握

外部マクロ環境要因は、月経前症候群の治療市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析月経前症候群の治療市場における競合情勢の把握

月経前症候群の治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス月経前症候群の治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、月経前症候群の治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨月経前症候群の治療市場における成功への道筋を描く

月経前症候群の治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 月経前症候群に関する診断の認知度向上
    • PMS治療製品をオンラインチャネルを通じて簡単に入手できる
  • 抑制要因
    • PMS医薬品および機器の製品リコールに関連する問題
  • 機会
    • PMS治療の進歩と新薬の登場
    • ウェアラブル技術の導入とデジタルヘルスの普及
  • 課題
    • PMS管理に関する社会的障壁と偏見
• 市場セグメンテーション分析
  • 薬剤の種類：避妊と症状管理の二重の役割を果たすことから、PMS症状の管理に経口避妊薬が利用されるようになってきています。
  • 流通チャネル：顧客の便利なショッピングニーズにより、eコマースの流通チャネルが好まれるようになっている
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 月経前症候群の治療市場薬の種類別

• 抗うつ薬
• 利尿剤
• 非ステロイド性抗炎症薬（NSAID）
• 経口避妊薬および卵巣抑制剤

第7章 月経前症候群の治療市場：タイプ別

• 店頭
• 処方箋

第8章 月経前症候群の治療市場：流通チャネル別

• eコマース
• 病院
• 小売薬局

第9章 南北アメリカの月経前症候群の治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の月経前症候群の治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの月経前症候群の治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • ビスタジェン、月経前不快気分障害の症状の急性期管理のためのPH80の探索的第2A相試験で良好な結果を発表
  • サーティ・マディソンは、ザ・ピル・クラブからの戦略的資産買収を通じて何千人もの患者に継続的なケアを提供し、女性の健康における地位を強化します。
  • ロンドンを拠点とするニューロテックのスタートアップ企業が月経症状用の医療機器を開発
• 戦略分析と提言

企業一覧

• AA Pharma Inc.
• Alfa Pharma GmbH
• Asarina Pharma AB.
• ASKA Pharmaceutical Co., Ltd.
• Aurobindo Pharma
• Bayer AG
• Cadila Pharmaceuticals.
• Comforte Cream by PMS4PMS, LLC
• Dr. Reddy's Laboratories Inc.
• GlaxoSmithKline plc
• Intas Pharmaceuticals Ltd.
• Lupin Limited
• Mylan N.V.
• Par Pharmaceutical, Inc
• Pfizer Inc.
• Samphire Neuroscience
• Shine Pharmaceuticals Limited
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• The Himalaya Drug Company
• Vitane Pharmaceuticals, Inc.

LIST OF FIGURES

• FIGURE 1. PREMENSTRUAL SYNDROME TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. PREMENSTRUAL SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. PREMENSTRUAL SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PREMENSTRUAL SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. PREMENSTRUAL SYNDROME TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DIURETICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES & OVARIAN SUPPRESSION AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 29. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 30. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 31. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 46. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 47. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 48. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 49. INDIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 50. INDIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 51. INDIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 101. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 102. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 103. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 113. POLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 114. POLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 115. POLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 116. QATAR PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 117. QATAR PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 118. QATAR PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 146. PREMENSTRUAL SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 147. PREMENSTRUAL SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

The Premenstrual Syndrome Treatment Market was valued at USD 1.72 billion in 2023, expected to reach USD 1.79 billion in 2024, and is projected to grow at a CAGR of 4.35%, to USD 2.32 billion by 2030.

Premenstrual Syndrome (PMS) Treatment Market is centered around the array of therapies and products designed to alleviate symptoms of PMS, which affects a significant proportion of menstruating individuals. The necessity of this market is underscored by the widespread prevalence of PMS, which can cause physical, emotional, and behavioral symptoms, substantially impacting daily activities and quality of life. Applications of PMS treatments span from over-the-counter medications, supplements, and lifestyle modifications to prescription therapies, tailored to address specific symptoms like mood swings, bloating, and cramps. End-users primarily encompass individuals seeking relief from these symptoms, including both those self-treating and those under medical supervision. Growth in this market is significantly influenced by increasing awareness, advances in women's healthcare, and a rising preference for personalized medicine. Opportunities exist in developing hormone-based treatments, plant-based remedies, and digital health solutions for symptom tracking and management. However, the market faces limitations such as side effects of current treatments, and societal stigma that hinders open discussions and diagnosis, coupled with regulatory challenges in approving new therapies. Additionally, the absence of a one-size-fits-all treatment due to the multifaceted nature of PMS presents challenges. Innovations could be explored in non-hormonal treatment options, artificial intelligence for personalized treatments, and mobile health technologies to enhance patient engagement. Research into specific genetic, hormonal, and lifestyle factors that contribute to PMS could offer insights for more targeted interventions. The PMS treatment market is dynamic, with continuous demand for effective solutions that provide comprehensive symptom relief. Businesses have the potential to capitalize on unmet needs by focusing on patient-centric approaches, creating awareness campaigns to reduce stigma, and collaborating with healthcare professionals to optimize treatment protocols, thereby fostering market growth and improving patient outcomes.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Premenstrual Syndrome Treatment Market

The Premenstrual Syndrome Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing awareness of diagnosis regarding premenstrual syndrome
  • Easy availability of PMS treatment products through online channels
• Market Restraints
  • Issues associated with product recalls for PMS drugs and devices
• Market Opportunities
  • Advancements in therapy for PMS and the emergence of novel drugs
  • Adoption of wearable technology and the proliferation of digital health
• Market Challenges
  • Societal barriers and stigmatization regarding PMS management

Porter's Five Forces: A Strategic Tool for Navigating the Premenstrual Syndrome Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Premenstrual Syndrome Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Premenstrual Syndrome Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Premenstrual Syndrome Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Premenstrual Syndrome Treatment Market

A detailed market share analysis in the Premenstrual Syndrome Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Premenstrual Syndrome Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Premenstrual Syndrome Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Premenstrual Syndrome Treatment Market

A strategic analysis of the Premenstrual Syndrome Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Premenstrual Syndrome Treatment Market, highlighting leading vendors and their innovative profiles. These include AA Pharma Inc., Alfa Pharma GmbH, Asarina Pharma AB., ASKA Pharmaceutical Co., Ltd., Aurobindo Pharma, Bayer AG, Cadila Pharmaceuticals., Comforte Cream by PMS4PMS, LLC, Dr. Reddy's Laboratories Inc., GlaxoSmithKline plc, Intas Pharmaceuticals Ltd., Lupin Limited, Mylan N.V., Par Pharmaceutical, Inc, Pfizer Inc., Samphire Neuroscience, Shine Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., The Himalaya Drug Company, and Vitane Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Premenstrual Syndrome Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Type, market is studied across Antidepressants, Diuretics, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), and Oral Contraceptives & Ovarian Suppression Agents.
• Based on Type, market is studied across Over-the-Counter and Prescription.
• Based on Distribution Channel, market is studied across E-commerce, Hospitals, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing awareness of diagnosis regarding premenstrual syndrome
    • 5.1.1.2. Easy availability of PMS treatment products through online channels
  • 5.1.2. Restraints
    • 5.1.2.1. Issues associated with product recalls for PMS drugs and devices
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in therapy for PMS and the emergence of novel drugs
    • 5.1.3.2. Adoption of wearable technology and the proliferation of digital health
  • 5.1.4. Challenges
    • 5.1.4.1. Societal barriers and stigmatization regarding PMS management
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug Type: Emerging utilization of oral contraceptives for managing PMS symptoms due to their dual role in birth control and symptom management
  • 5.2.2. Distribution Channel: Emerging preference for e-Commerce distribution channels due to customer need for convenient shopping
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Premenstrual Syndrome Treatment Market, by Drug Type

• 6.1. Introduction
• 6.2. Antidepressants
• 6.3. Diuretics
• 6.4. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
• 6.5. Oral Contraceptives & Ovarian Suppression Agents

7. Premenstrual Syndrome Treatment Market, by Type

• 7.1. Introduction
• 7.2. Over-the-Counter
• 7.3. Prescription

8. Premenstrual Syndrome Treatment Market, by Distribution Channel

• 8.1. Introduction
• 8.2. E-commerce
• 8.3. Hospitals
• 8.4. Retail Pharmacies

9. Americas Premenstrual Syndrome Treatment Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Premenstrual Syndrome Treatment Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Premenstrual Syndrome Treatment Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder
  • 12.3.2. Thirty Madison Delivers Continuity Of Care For Thousands Through Strategic Asset Purchase From The Pill Club, Strengthening Its Position In Women's Health
  • 12.3.3. London-Based Neurotech Start-Up Develops Medical Device For Menstrual Symptoms
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AA Pharma Inc.
• 2. Alfa Pharma GmbH
• 3. Asarina Pharma AB.
• 4. ASKA Pharmaceutical Co., Ltd.
• 5. Aurobindo Pharma
• 6. Bayer AG
• 7. Cadila Pharmaceuticals.
• 8. Comforte Cream by PMS4PMS, LLC
• 9. Dr. Reddy's Laboratories Inc.
• 10. GlaxoSmithKline plc
• 11. Intas Pharmaceuticals Ltd.
• 12. Lupin Limited
• 13. Mylan N.V.
• 14. Par Pharmaceutical, Inc
• 15. Pfizer Inc.
• 16. Samphire Neuroscience
• 17. Shine Pharmaceuticals Limited
• 18. Sun Pharmaceutical Industries Ltd.
• 19. Teva Pharmaceutical Industries Ltd.
• 20. The Himalaya Drug Company
• 21. Vitane Pharmaceuticals, Inc.